Abstract
Marine sources have attracted much attention as potential sources for natural products over recent years. The future of the biopharmaceutical holds great promise due to the many compounds that have and will be isolated from marine sources. Marine organisms have long been recognized as a source of novel metabolites with applications in human disease therapy. The marine environment is a rich source of both biological and chemical diversity, where it has been reported that oceans contain nearly 300,000 described species, representing only a small percentage of the total number of species that have to be discovered. The ocean represents a rich resource for ever more novel compounds with great potential as pharmaceutical, nutritional supplements, cosmetics, agrichemicals and enzymes, where each of these marine bioproducts has a strong potential market value. The reasons for the strong showing of drug discovery from natural products can be attributed to the diverse structures, intricate carbon skeletons, and the ease that human bodies will accept these molecules with minimal manipulation. With new pressures from the public and governments around the world to develop products to combat diseases and infections commonly encountered, new chemical entities need to be found and developed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnold, L. Demain and Sanchez Sergio (2009). Microbial drug discovery: 80 years of progress. The Journal of Antibiotics, 62: 5-16.
Balaban, N. and G. Dell’Acqua (2005). Barriers on the road to new antibiotics. Scientist, 19: 42-43.
Balick, M.J. and P.A. Cox (1996). Plants, People and Culture. The Science of Ethnobotany. Scientific American Library, New York.
Berdy, J. (2005). Bioactive microbial metabolites. A personal view. J. Antibiot., 58: 1-26.
Blunt, J.W., Copp, B.R., Munro, M.H.G., Northcote, P.T. and M.R. Prinsep (2005). Nat. Prod. Rep., 22: 15.
Bourguet-Kondracki, M.L. and J.M. Kornprobst (2005). Marine Pharmacology: Potentialities in the Treatment of Infectious Diseases, Osteoporosis, and Alzheimer's Disease. Adv Biochem Engin/Biotechnol., 97: 105-131.
Bull, A.T., Stach, J.E.M., Ward, A.C. and M. Goodfellow (2005). Antonie van Leeuwenhoek, 87: 65.
Butler, M.S. (2004). The role of natural product chemistry in drug discovery. J. Nat. Prod., 67: 2141-2153.
Christie, S.N., McCaughey, C., McBride, M. and P.V. Coyle (1997). Herpes simplex type 1 and genital herpes in Northern Ireland. Int J STD AIDS, 8: 68-69.
Constantino, V, Fattorusso, E., Menna, M. and O. Taglialatela-Scafati (2004). Chemical diversity of bioactive marine natural products: an illustrative case study. Current Medicinal Chemisty 11: 1671-1692.
Cragg, G.M., Newman, D.J. and K.M. Snader (1997). Natural products in drug discovery and development. J. Nat.Prod., 60: 52-60.
Cragg, G.M. and D.J. Newman (2001). Medicinals for the millennia. The historical record. Ann. NYAcad. Sci., 953a: 3-25.
Colwell, R.R. (2002). Fulfilling the promise of biotechnology. Biotechnol. Adv., 20: 215-228.
Cragg, G.M., Newman, D.J. and S.S. Yang (2006). Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J. Nat. Prod., 69: 488-498.
De Vries, D.J. and P.M. Beart (1995). Fishing for drugs from the sea: status and strategies. Trends Pharmacol Sci., 16: 275-279.
Faulkner, D.J. (2000). Highlights of marine natural products chemistry (1972’1999). Nat. Prod. Rep, 17: 1-6.
Faulkner, J. (2002). Marine natural products. Nat. Prod. Rep., 19: 1-48.
Feling, R.H., Buchanan, G.O., Mincer, T.J., Kauffman, C.A., Jensen, P.R. and W. Fenical (2003). Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed., 42: 355-357.
Hancock, R.E.W. (2007). The end of an era? Nat. Rev. Drug Discov., 6: 26.
Haefner, B. (2003). Drugs from the deep: Marine natural products as drug candidates. Drug Discov Today; 8: 536-544.
Hale, K.J., Hummersone, M.G., Manaviazar, S. and M. Frigerio (2002). The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep., 19: 413-453.
Isaka, M., Suyarnsestakorn, C., Tanticharoen, M., Kongsaeree, P. and Y. Thebtaranonth (2002). Aigialomycins A–E, new resorcylic macrolides from the marine mangrove fungus Aigialus parvus. J. Org. Chem., 67:1561-1566.
Jung, W.S. et al. (2006). Heterologous expression of tylosin polyketide synthase and production of a hybrid bioactive macrolide in Streptomyces venezuelae. Appl. Microbiol. Biotechnol., 72: 763-769.
Katz, M.L., Mueller, L.V., Polyakov, M. and S.F. Weinstock (2006). Where have all the antibiotic patents gone? Nat. Biotechnol., 24: 1529-1531.
Kijjoa, A. and P. Sawangwong (2004). Drugs and cosmetics from the sea. Marine Drugs, 2: 73-82.
Kim, T.K., Garson, M.J. and J.A. Fuerst (2005). Marine actinomycetes related to the ‘Salinospora’ group from the Great Barrier Reef sponge Pseudoceratina clavata. Environ Microbiol., 7: 509-518.
Kin, S. Lam. (2006). Discovery of novel metabolites from marine actinomycetes. Current Opinion in Microbiology, 9: 245-251.
Kuhlmann, J. (1997). Drug research: From the idea to the product. International Journal of Clinical Pharmacology & Therapeutics, 35: 541-542.
Konig, G.M., Wright, A.D., Sticher, O., Angerhofer, C.K. and J.M. Pezzuto (1994). Biological activities of selected marine natural products. Planta Med., 60: 532-537.
Kwon, H.C. et al. (2006). Marinomycins A–D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus ‘Marinispora’. J. Am. Chem. Soc, 128: 1622-1632.
Lederberg, J. (2000). Infectious history. Science, 288: 287-293.
Malakoff, D. (1997). Extinction on the high seas. Science, 277: 486-488.
Martin, V.J. et al. (2003). Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol., 21: 796-802.
Mazor, Y. (2007). Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol., 25: 563-565.
Minami, H. (2008). Microbial production of plant benzylisoquinoline alkaloids. Proc. Natl. Acad. Sci. U.S.A., 105: 7393-7398.
Morse, S.S. (1997). The public health threat of emerging viral disease. J. Nutr., 127: 951S-957S.
Narsinh, L. Thakur (2008). Marine Molecular Biology: An emerging field of biological sciences. Biotechnology Advances, 26: 233-245.
Newman, D.J., Cragg, G.M and K.M. Snader (2003). Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66: 1022-1037.
Nguyen, K.T. et al. (2006). Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl. Acad. Sci. U.S.A., 103: 17462-17467.
Patrzykat, A. and S.E. Douglas (2003). Gone gene fishing: how to catch novel marine antimicrobials. Trends in Biotechnology., 21: 362-369.
Rayl, A.J.S. (1999). Oceans: medicine chests of the future? Scientist, 13: 1-5.
Redfield, A.C. (1958). The biological control of chemical factors in the environment. Am. Sci., 46: 205-221.
Rowley, D.C., Hansen, M.S., Rhodes, D., Sotriffer, C.A., Ni, H., McCammon, J.A., Bushman, F.D. and W. Fenical (2002). Thalassiolins A–C: New marine-derived inhibitors of HIV cDNA integrase. Bioorg. Med. Chem., 10: 3619-3625.
Sang, Yup Lee (2009). Microorganisms: general strategies and drug production. Drug Discovery Today, 14(1/2): 78-88.
Schwartsmann, G., Da Rocha, A.B., Mattei, J. and R. Lopes (2003). Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs, 12: 1367-1383.
Sipkema, D., Franssen, M.C.R., Osinga, R., Tramper, J. and R.H. Wijffels (2005). Mar. Biotechnol., 7: 142.
Sudek, S. (2007). Identification of the putative bryostatin polyketide synthase gene clusters from ‘Candidatus Endobugula sertula’, the uncultivated microbial symbiont of the marine byrozoan Bugula neritina. J. Nat. Prod., 70: 67-74.
Thayer, A.M. (1998). Chemical & Engineering News February 23, 25.
Tziveleka, L.A., Vagias, C. and V. Roussis (2003). Natural products with anti-HIV activity from marine organisms. Curr Top Med Chem., 3: 1512-1535.
Vignesh, S., Raja, A. and R. Arthur James (2011). Marine Drugs: Implication and Future Studies. International Journal of Pharmacology, 7(1): 22-30.
Wang, C.Y., Geng, M.Y. and H.S. Guan (2005). Chin. J. New Drugs, 14: 278.
Website: Drugs from the sea: will the next penicillin come from a sponge? (Florida Atlantic University) http://www.science.fau.edu/drugs.htm.
William Fenical (2006). Marine pharmaceuticals: Past, present and future. Oceanography, 19(2): 75-78.
Zhang, Z. (2004). A new strategy for the synthesis of glycoproteins. Science, 303: 371-373.
Zhang, L., An, R., Wang, R., Sun, N., Zhang, S., Hu, J. and J. Kuai (2005). Isolation of novel bioactive compounds from marine microbes. Curr. Opin. Microbiol., 8: 276-281.
Zubia, E., Ortega, M.J. and J. Salva (2005). Mini-Rev. Org. Chem, 2: 389.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Capital Publishing Company
About this chapter
Cite this chapter
James, R.A., Vignesh, S., Muthukumar, K. (2012). Marine Drugs Development and Social Implication. In: Subramanian, V. (eds) Coastal Environments: Focus on Asian Regions. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3002-3_15
Download citation
DOI: https://doi.org/10.1007/978-90-481-3002-3_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3001-6
Online ISBN: 978-90-481-3002-3
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)